Using a mouse model of tauopathy, we applied a therapeutic approach involving activation of the immune system by blockade of the PD-1/PD-L1 inhibitory pathway, which was previously shown to be beneficial in modifying AD and tauopathy [11, 19]. The gene discussed is PDCD1; the disease is tauopathy.